Assessing the effects of risankizumab on ulcerative colitis in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of risankizumab in treating adult patients with moderate to severe ulcerative colitis in real-world clinical settings. Approximately 200 participants will be enrolled across multiple sites in Germany and Austria, receiving risankizumab as prescribed by their physicians. The study will monitor changes in disease activity over a period of up to 52 weeks, with no additional burden placed on participants beyond their routine clinical visits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with an endoscopically confirmed diagnosis of moderate to severe ulcerative colitis.
* Participants initiating risankizumab at the investigator's discretion as part of their routine clinical care; the decision to administer risankizumab must be made prior to and independent of documentation for the study and according to the approved local label.

Exclusion Criteria:

* Participants previously exposed risankizumab
* Participants who are currently participating in interventional research (not including noninterventional studies, post-marketing observational study (PMOS), or registry participation).

Where it's running

• Universitaetsklinikum Heidelberg /ID# 275906
  Heidelberg, Baden-Wurttemberg, Germany Recruiting
• Klinikum Ernst Von Bergmann /ID# 278268
  Potsdam, Brandenburg, Germany Recruiting
• Private Practice Dr. Katharina Pfeifer /ID# 286373
  Wriezen, Brandenburg, Germany Recruiting
• Private Practice - Dr. Kempelmann /ID# 275726
  Tostedt, Free and Hanseatic City of Hamburg, Germany Recruiting
• Gastroenterologische Schwerpunktpraxis - Hannover /ID# 276701
  Hanover, Lower Saxony, Germany Recruiting
• Praxis fuer Gastroenterologie - Schwerin /ID# 275946
  Schwerin, Mecklenburg-Vorpommern, Germany Recruiting

+7 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Medical Information Germany
• Email: medinfo.germany@abbvie.com
• Phone: 49 611 1720 1520

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Risankizumab for moderate to severe ulcerative colitis in Japanese adults: change in disease activity

  We will see if risankizumab, given as part of routine care, improves disease activity in Japanese adults with moderate to severe ulcerative colitis.

  Recruiting at 29 sites AbbVie · Nagakute, Aichi-ken and 28 other locations · NCT07136116

• How risankizumab works in children and teens with ulcerative colitis

  This trial tests risankizumab in children and adolescents with moderate to severe ulcerative colitis to see how the medicine moves through their bodies and whether it is safe and helps their condition.

  Recruiting at 73 sites Phase 3 AbbVie · Phoenix, Arizona and 72 other locations · NCT07071519

• Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy

  This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.

  Recruiting at 5 sites Austin Health · Hobart and 6 other locations · NCT07916727

• Risankizumab for Refractory Perianal Fistulizing Crohn's Disease

  This study tests whether risankizumab can help people with Crohn’s disease who have draining perianal fistulas not responding to other treatments.

  Recruiting Phase 4 Hyogo Medical University · Nishinomiya and 3 other locations · NCT07872449

• A Probiotic Approach to Modulating Gut Microbiota in Mild-to-Moderate Ulcerative Colitis

  A specific probiotic given rectally will be tested in adults with mild-to-moderate ulcerative colitis to see if it can help manage symptoms.

  Recruiting Catholic University of the Sacred Heart · Roma, RM · NCT07724990

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.